Additionally, CB2 heterodimerization with human epidermal growth factor receptor 2 (HER2) and C-X-C chemokine receptor type 4 activates CB2 and inhibits signaling of the aforementioned (word for HER2 and C-X-C), suggesting its potential as an anti-tumor therapeutic [37]. Here, ERBB2 is linked to neoplasm.